{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-24-005965","form_type":"8-K","ticker":"EDSA","cik":"0001540159","company_name":"Edesa Biotech, Inc.","filed_at":"2024-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.902824+00:00","generated_at":"2026-06-02T03:39:24.220531+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Edesa Biotech Q2 FY2024 net loss $1.9M ($0.58/shr); advances ARDS Phase 3 and vitiligo study","bullets":["Net loss narrowed to $1.9M vs $2.3M YoY; six-month loss $3.5M ($1.12/shr).","Cash $2.8M at March 31; received $0.7M post-quarter from Canadian govt funding.","Expanding Phase 3 ARDS trial with EB05; up to C$23M govt support secured.","Plans to file IND for Phase 2 pulmonary fibrosis study with EB05.","Seeks U.S. approval for Phase 2 vitiligo study; pursuing strategic deals for EB01."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-24-005965","json":"https://secwatch.observer/filing/0001654954-24-005965.json","markdown":"https://secwatch.observer/filing/0001654954-24-005965.md","text":"https://secwatch.observer/filing/0001654954-24-005965.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1540159/000165495424005965/0001654954-24-005965-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1540159/000165495424005965/edsa_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T03:39:24.220531+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0e3cb1e3c683fa048ff4ac48601c44d33c8132a3","claim":"Edesa Biotech, Inc. reported the three and six months ended March 31, 2024 results: net income $1.9 million for the quarter ended March 31, 2024, EPS $0.58 per common share.","evidence_excerpt":"For the quarter ended March 31, 2024, Edesa reported a net loss of $1.9 million, or $0.58 per common share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1540159/000165495424005965/0001654954-24-005965-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three and six months ended March 31, 2024"},{"label":"Net income","value":"$1.9 million for the quarter ended March 31, 2024"},{"label":"EPS","value":"$0.58 per common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"b508f0322ad19d014398dcc15513f9489806b9b8","claim":"Edesa Biotech, Inc. reported the six months ended March 31, 2024 results: net income $3.5 million for the six months ended March 31, 2024, EPS $1.12 per common share.","evidence_excerpt":"For the six months ended March 31, 2024, Edesa reported a net loss of $3.5 million, or $1.12 per common share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1540159/000165495424005965/0001654954-24-005965-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the six months ended March 31, 2024"},{"label":"Net income","value":"$3.5 million for the six months ended March 31, 2024"},{"label":"EPS","value":"$1.12 per common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}